60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc.
Your view on SXTP
Overview
What the company does, where it operates, and who runs it.
About 60 Degrees Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Geoffrey Stuart Dow
- Headquarters
- 1025 Connecticut Avenue NW, Washington, DC, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Geoffrey Stuart Dow
- Headquarters
- 1025 Connecticut Avenue NW, Washington, DC, US
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment.
It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue.
The company was founded in 2010 and is based in Washington, District of Columbia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for 60 Degrees Pharmaceuticals, Inc., and the rating behind it. SXTP last traded at $0.90; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for 60 Degrees Pharmaceuticals, Inc.. Starting points for 60 Degrees Pharmaceuticals, Inc.: EPS -$3.06, beta 2.54 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for 60 Degrees Pharmaceuticals, Inc.. 60 Degrees Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for 60 Degrees Pharmaceuticals, Inc.. Trailing twelve-month EPS for 60 Degrees Pharmaceuticals, Inc. stands at -$3.06. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for 60 Degrees Pharmaceuticals, Inc.. 60 Degrees Pharmaceuticals, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
60 Degrees Pharmaceuticals, Inc. valued side by side against its closest peers. 60 Degrees Pharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold 60 Degrees Pharmaceuticals, Inc., and how their positions are changing. At a $725,895 market value, institutional positions materially move 60 Degrees Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by 60 Degrees Pharmaceuticals, Inc. executives and directors. Shares of 60 Degrees Pharmaceuticals, Inc. have traded between $0.85 and $12.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming 60 Degrees Pharmaceuticals, Inc.. 60 Degrees Pharmaceuticals, Inc. is a $725,895 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming 60 Degrees Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for 60 Degrees Pharmaceuticals, Inc.. Coverage tracks 60 Degrees Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.